Daniel Swinson

2.7k total citations · 1 hit paper
45 papers, 1.4k citations indexed

About

Daniel Swinson is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Daniel Swinson has authored 45 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 14 papers in Surgery and 13 papers in Oncology. Recurrent topics in Daniel Swinson's work include Gastric Cancer Management and Outcomes (12 papers), Esophageal Cancer Research and Treatment (10 papers) and Lung Cancer Treatments and Mutations (7 papers). Daniel Swinson is often cited by papers focused on Gastric Cancer Management and Outcomes (12 papers), Esophageal Cancer Research and Treatment (10 papers) and Lung Cancer Treatments and Mutations (7 papers). Daniel Swinson collaborates with scholars based in United Kingdom, Ireland and United States. Daniel Swinson's co-authors include Kenneth J. O’Byrne, J. Louise Jones, John Edwards, G. Cox, Donna Richardson, David Waller, Jonathan Wadsley, Stephen Falk, Srinivasan Madhusudan and David Cunningham and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Daniel Swinson

42 papers receiving 1.4k citations

Hit Papers

Docetaxel versus active symptom control for refractory oe... 2013 2026 2017 2021 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
    2013 405 citations Hugo Ford, Andrea Marshall et al. The Lancet Oncology profile →

Peers

Daniel Swinson
Ken Shimada Japan
Angelica Petrillo Italy
Mitsukuni Suenaga Japan
Sarita Dubey United States
Sang‐Ho Jeong South Korea
Carmelo Pozzo Italy
R. Morant Switzerland
Joyce Thompson United Kingdom
Encarnación González‐Flores Spain
Hideyuki Mishima Japan
Ken Shimada Japan
Daniel Swinson
Citations per year, relative to Daniel Swinson Daniel Swinson (= 1×) peers Ken Shimada

Countries citing papers authored by Daniel Swinson

Since Specialization
Citations

This map shows the geographic impact of Daniel Swinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Swinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Swinson more than expected).

Fields of papers citing papers by Daniel Swinson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Swinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Swinson. The network helps show where Daniel Swinson may publish in the future.

Co-authorship network of co-authors of Daniel Swinson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Swinson. A scholar is included among the top collaborators of Daniel Swinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Swinson. Daniel Swinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pini, Simon, Kate Flemming, Marie Fallon, et al.. (2023). Exploration of pain assessment and management processes in oncology outpatient services with healthcare professionals: a qualitative study. BMJ Open. 13(12). e078619–e078619. 4 indexed citations
2.
Ashley, Laura, Ian Kellar, Lisa Kidd, et al.. (2022). Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians. BMJ Open. 12(2). e060402–e060402. 3 indexed citations
3.
Swinson, Daniel, David A. Cairns, Mark Baxter, et al.. (2021). Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial. Journal of Geriatric Oncology. 13(3). 287–293. 12 indexed citations
4.
Zakeri, Nekisa, Yuk Ting, Joanne O’Rourke, et al.. (2021). Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. British Journal of Cancer. 125(10). 1350–1355. 28 indexed citations
5.
Dearden, Helen Clare, Mark Baxter, Sally Martin, et al.. (2021). Observational study investigating Tolerance Of Anticancer Systemic Therapy In the Elderly (TOASTIE): a protocol. BMJ Open. 11(9). e051104–e051104. 1 indexed citations
6.
Jain, Prashant, et al.. (2020). The Potential Role of Radiotherapy in the Management of Hepatoid Carcinomas of the Stomach: A Case Report. Oncology Research and Treatment. 43(4). 170–174. 4 indexed citations
7.
Langley, Ruth E., Richard H. Wilson, Fay Cafferty, et al.. (2019). Aspirin as adjuvant treatment for colorectal cancer: Rationale and progress of the Add-Aspirin trial.. Journal of Clinical Oncology. 37(15_suppl). TPS3624–TPS3624. 1 indexed citations
8.
Ajani, Jaffer A., Anghel Adrian Udrea, Tomasz Sarosiek, et al.. (2017). A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB. Annals of Oncology. 28. v238–v238. 3 indexed citations
9.
Folprecht, Gunnar, Carles Pericay, Mark Saunders, et al.. (2016). Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Annals of Oncology. 27(7). 1273–1279. 61 indexed citations
10.
King, James P., Daniel H. Palmer, Philip J. Johnson, et al.. (2016). Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit. Clinical Oncology. 29(4). 256–262. 28 indexed citations
11.
Ford, Hugo, Andrea Marshall, Jonathan Wadsley, et al.. (2013). COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology. 31(4_suppl). LBA4–LBA4. 20 indexed citations
12.
Ford, Hugo, Andrea Marshall, John Bridgewater, et al.. (2013). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The Lancet Oncology. 15(1). 78–86. 405 indexed citations breakdown →
13.
14.
Edwards, John, Daniel Swinson, J. Louise Jones, David Waller, & Kenneth J. O’Byrne. (2006). EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer. 54(3). 399–407. 65 indexed citations
15.
Swinson, Daniel, et al.. (2005). Phase II trial of first-line gefitinib in patients unsuitable for chemotherapy with stage III/IV non-small-cell lung cancer. Journal of Clinical Oncology. 23(16_suppl). 7256–7256. 6 indexed citations
16.
Swinson, Daniel, G. Cox, & Kenneth J. O’Byrne. (2004). Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. British Journal of Cancer. 91(7). 1301–1307. 3 indexed citations
17.
18.
Edwards, John, Daniel Swinson, J. Louise Jones, et al.. (2003). Tumor Necrosis Correlates With Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma *. CHEST Journal. 124(5). 1916–1923. 86 indexed citations
19.
Swinson, Daniel, J. Louise Jones, Donna Richardson, et al.. (2002). Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer. 37(3). 235–240. 144 indexed citations
20.
O’Byrne, Kenneth J., G. Cox, Daniel Swinson, et al.. (2001). Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer. 34. S83–S89. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ken Shimada Breakdown of academic impact, for papers by Angelica Petrillo Breakdown of academic impact, for papers by Mitsukuni Suenaga Breakdown of academic impact, for papers by Sarita Dubey Breakdown of academic impact, for papers by Sang‐Ho Jeong Breakdown of academic impact, for papers by Carmelo Pozzo Breakdown of academic impact, for papers by R. Morant Breakdown of academic impact, for papers by Joyce Thompson Breakdown of academic impact, for papers by Encarnación González‐Flores Breakdown of academic impact, for papers by Hideyuki Mishima
Rankless by CCL
2026